Metabolic Response to XD14 Treatment in Human Breast Cancer Cell Line MCF-7
Daqiang Pan1,2, Michel Kather3, Lucas Willmann4,5
1Center for Biological Systems Analysis ZBSA, Albert-Ludwigs-University Freiburg, 79104 Freiburg, Germany. daqiang.pan@mail.zbsa.uni-freiburg.de.
Abstract:
XD14 is a 4-acyl pyrrole derivative, which was discovered by a high-throughput virtual screening experiment. XD14 inhibits bromodomain and extra-terminal domain (BET) proteins (BRD2, BRD3, BRD4 and BRDT) and consequently suppresses cell proliferation. In this study, metabolic profiling reveals the molecular effects in the human breast cancer cell line MCF-7 (Michigan Cancer Foundation-7) treated by XD14. A three-day time series experiment with two concentrations of XD14 was performed. Gas chromatography-mass spectrometry (GC-MS) was applied for untargeted profiling of treated and non-treated MCF-7 cells. The gained data sets were evaluated by several statistical methods: analysis of variance (ANOVA), clustering analysis, principle component analysis (PCA), and partial least squares discriminant analysis (PLS-DA). Cell proliferation was strongly inhibited by treatment with 50 µM XD14. Samples could be discriminated by time and XD14 concentration using PLS-DA. From the 117 identified metabolites, 67 were significantly altered after XD14 treatment. These metabolites include amino acids, fatty acids, Krebs cycle and glycolysis intermediates, as well as compounds of purine and pyrimidine metabolism. This massive intervention in energy metabolism and the lack of available nucleotides could explain the decreased proliferation rate of the cancer cells.
Insights
XD14, a bromodomain and extra-terminal domain (BET) protein inhibitor, significantly suppressed breast cancer cell proliferation. Metabolic profiling revealed widespread alterations in energy and nucleotide metabolism following XD14 treatment.
Area of Science:
- Biochemistry
- Cancer Biology
- Metabolomics
Background:
- Bromodomain and extra-terminal domain (BET) proteins are epigenetic regulators implicated in cancer.
- XD14 is a novel 4-acyl pyrrole derivative identified via high-throughput virtual screening.
- BET proteins (BRD2, BRD3, BRD4, BRDT) play crucial roles in cell proliferation and are targeted in cancer therapy.
Purpose of the Study:
- To investigate the metabolic effects of XD14 on the human breast cancer cell line MCF-7.
- To understand the molecular mechanisms underlying XD14-induced suppression of cancer cell proliferation.
- To identify specific metabolic pathways affected by XD14 treatment.
Main Methods:
- Untargeted metabolic profiling using Gas Chromatography-Mass Spectrometry (GC-MS).
- Time-series experiments with two concentrations of XD14 (50 µM) on MCF-7 cells over three days.
- Statistical analysis including ANOVA, PCA, and PLS-DA for data evaluation.
Main Results:
- XD14 treatment strongly inhibited MCF-7 cell proliferation at 50 µM.
- PLS-DA successfully discriminated samples based on time and XD14 concentration.
- 67 out of 117 identified metabolites were significantly altered, including amino acids, fatty acids, and intermediates of central carbon and nucleotide metabolism.
Conclusions:
- XD14 profoundly impacts cellular energy metabolism and nucleotide biosynthesis in breast cancer cells.
- The observed metabolic perturbations, particularly the depletion of nucleotides, likely contribute to the antiproliferative effects of XD14.
- XD14 represents a promising therapeutic agent targeting BET proteins and impacting cancer cell metabolism.
